Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00462943
- Locations
- 🇨🇦
Teva Investigational Site 313, Montreal, Canada
🇫🇷Teva Investigational Site 327, Strasbourg, France
🇺🇸Teva Investigational Site 303, Los Angeles, California, United States
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00375219
- Locations
- 🇺🇸
Teva Investigational Site 003, Los Angeles, California, United States
🇫🇷Teva Investigational Site 029, Bordeaux, France
🇫🇷Teva Investigational Site 021, Le Chesnay Cedex, France
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 306
- Registration Number
- NCT00349193
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2011-10-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1155
- Registration Number
- NCT00337779
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
- Conditions
- Multiple Sclerosis
- Interventions
- Procedure: NAbs testing
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1230
- Registration Number
- NCT00336557
- Locations
- 🇺🇸
Neuro-Pain Medical Center, Fresno, California, United States
🇺🇸Fullerton Neurology and Headache Center, Fullerton, California, United States
🇺🇸East Bay Physicians Medical Group, Berkley, California, United States
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
- First Posted Date
- 2006-03-30
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT00308685
- Locations
- 🇺🇸
Allergy & Asthma Specialist Medical Group, Huntington Beach, California, United States
🇺🇸Little Rock Allergy and Asthma, Little Rock, Arkansas, United States
🇺🇸Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States
Safety and Efficacy of Talampanel in Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- Interventions
- Radiation: Radiation Therapy (RT) 5 days a week +Drug: temozolomide(TMZ) 75mgDrug: adjuvant TMZ 200mg
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00267592
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2012-01-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1174
- Registration Number
- NCT00256204
Non-invasive Measures of Distal Lung Disease in Asthmatics
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT00250341
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00240032